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As the population in most industrialized nations ages, 
the development of disease-modifying agents against 
Alzheimer’s disease (AD), the most common cause of 
dementia in the elderly, is one of the most important 
unmet medical needs in the world. Because of strong 
experimental support for amyloid-β (Aβ), a small peptide 
derived from the sequential cleavage of amyloid-β pre-
cursor protein (APP) by BACE1 and γ-secretase, as the 
principle culprit in this devastating neurodegenerative 
disease, investigators focused eﬀ   orts to develop com-
pounds designed to inhibit the activity of γ-secretase in 
order to attenuate β-amyloidosis as a potential therapy 
for AD [1]. However, Eli Lilly and Company announced 
last year that it was halting the development of semaga-
cestat, a ﬁ   rst-in-man γ-secretase inhibitor [2,3]. Two 
ongoing phase III studies showed that treatments using 
semagacestat were associated with worsening of clinical 
measures of cognition and the ability to perform activities 
of daily living, as well as an increased risk of skin cancer. 
Th   e exact molecular mechanisms underlying these   
adverse events remain unclear. However, semagacestat 
mechanis  tically inhibits not only γ-secretase to prevent 
Aβ pro  duc  tion but also Notch, one of the most important 
physiological substrates for γ-secretase in vivo [4]; 
genetic and pharmacological studies in mice supported 
the notion that the inhibition of γ-secretase caused 
toxicities by impacting Notch signaling. Th   e skin cancer 
risk was predicted from animal studies in which γ-
secretase/Notch signaling was globally attenuated [5,6]. 
Th  us, development of γ-secretase inhibitors/modulators 
that speciﬁ  cally inhibit the production of Aβ without in-
ﬂ  uenc  ing Notch activity is now necessary or mandatory 
as a treatment strategy for AD [2,7].
In a recent paper, Basi and co-workers at Elan Pharma-
ceuticals report a preclinical study of two novel 
sulfonamide-type small molecules, ELN318463 and 
ELN475516 [8]. Th   ese compounds showed predominant 
inhibitory potency against Aβ production over Notch 
signaling in vitro, suggesting that both molecules 
selectively inhibit APP cleavage by γ-secretase. Moreover, 
subchronic oral administration of one compound, 
ELN475516, signiﬁ  cantly reduced Aβ levels in brains of 
APP transgenic as well as wild-type mice. Importantly, 
treatment with ELN475516 did not show any inhibition 
of the expression of Notch target genes at the peripheral 
target, and no overt systemic toxicity was observed. 
Th  ese data indicate that it is possible to develop com-
pounds exhibiting APP-selective γ-secretase inhibition in 
vivo. Furthermore, Basi and colleagues revealed an 
intriguing ﬁ   nding regarding the molecular mechanism 
whereby these compounds confer APP selectivity by 
employing a chemical biology approach: only in the 
presence of the recombinant APP substrate were ELN 
compounds able to displace the active site isostere that 
directly targets both catalytic aspartates in PS1. In 
contrast, a non-selective classical inhibitor displaced the 
active site isostere from PS1 irrespective of the presence 
of the substrate, indicating that these ELN compounds 
selectively target the APP-cleaving PS1 conformation 
induced by the substrate. Th  ese data, therefore, suggest 
that APP-selective inhibition is feasible by developing 
small molecules that target the non-catalytic domains of 
γ-secretase. Supporting this notion, it has been reported 
that the substrate recognition mechanism in the 
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© 2011 BioMed Central Ltdγ-secretase is enzymatically distinct from the catalytic 
site, and that the substrate interaction induces an allo-
steric conformational change in the PS1 molecule [9]. 
Interest  ingly, Basi and colleagues have reported pre-
viously that this class of compounds, known as ‘Notch-
sparing γ-secretase inhibitors’ selectively inhibits PS1-
containing over PS2-containing γ-secretase [10]. Never-
theless, identiﬁ   cation of the molecular target and the 
precise binding site of ELN compounds may provide 
important progress towards the rational development of 
APP-selective γ-secretase inhibitors. Future structural 
analysis of this atypical membrane-embedded protease 
would shed light on the mechanism of APP selectivity. In 
addition, molecular analysis of such selectivity of ELN 
compounds versus other γ-secretase substrates might 
further clarify the mechanism-based advantage of these 
compounds. Importantly, recent genetic and chemical 
biology approaches revealed that there are several 
possible druggable target molecules within the γ-secre-
tase complex and the substrate [11-13]. In addition, after 
intensive eﬀ  orts several laboratories have recently developed 
γ-secretase modulators that selectively inhibit Aβ42 
production [14-16]. Combination approaches against 
several targets may be eﬀ  ective for reducing the levels of 
Aβ without inhibiting Notch in vivo [17]. In conclusion, 
Basi and colleagues provide strong evidence that it is 
possible to develop small APP-selective γ-secretase 
inhibitors that ‘spare’ Notch. Understanding the precise 
molecular mechanism whereby ELN compounds modu-
late the γ-secretase activity would pave the way to 
develop a potentially safe and eﬀ   ective compound to 
attenuate β-amyloidosis in AD.
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